Cardiovascular Properties of a Nitric Oxide Releasing Rofecoxib Analogue: Beneficial Anti‐hypertensive Activity and Enhanced Recovery in an Ischemic Reperfusion Injury Model

No abstract is available for this paper.

• Publication year

  2012

• Venue

  ChemMedChem

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cmdc.201200234PMID 22689528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rofecoxib Analogues Possessing a Nitric Oxide Donor Sulfohydroxamic Acid (SO2NHOH) Cyclooxygenase‐2 Pharmacophore: Synthesis, Molecular Modeling, and Biological Evaluation as Anti‐inflammatory Agents

  2012cited by this paper
• Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury

  2011cited by this paper
• Colony fusion and worker reproduction after queen loss in army ants

  2010cited by this paper
• Mechanisms of Cyclooxygenase-2 Inhibition and Cardiovascular Side Effects—The Plot Thickens

  2009cited by this paper
• The COXIB experience: a look in the rearview mirror.

  2009cited by this paper
• COX-2 and the Kidney

  2006cited by this paper
• Estrogen Replacement Effectively Improves the Accelerated Intimal Hyperplasia Following Balloon Injury of Carotid Artery in the Ovariectomized Rats

  2006cited by this paper
• Nitric oxide in myocardial ischemia/reperfusion injury.

  2004cited by this paper
• Nitric Oxide and Cardiac Function: Ten Years After, and Continuing

  2003cited by this paper
• Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects

  2003cited by this paper
• Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

  2002cited by this paper
• Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet

  2002cited by this paper
• Roles of Prostaglandin I2 and Thromboxane A2 in Cardiac Ischemia-Reperfusion Injury: A Study Using Mice Lacking Their Respective Receptors

  2001cited by this paper
• Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research.

  2001cited by this paper
• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  2001cited by this paper
• Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.

  1999cited by this paper
• The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

  1999cited by this paper
• The physiological role of nitric oxide

  1993cited by this paper

• New pyrazole-pyridazine hybrids as selective COX-2 inhibitors: design, synthesis, molecular docking, in silico studies and investigation of their anti-inflammatory potential by evaluation of TNF-α, IL-6, PGE-2 and NO in LPS-induced RAW264.7 macrophages.

  2024cites this paper
• Evaluation of the Inhibitory Effects of Pyridylpyrazole Derivatives on LPS-Induced PGE2 Productions and Nitric Oxide in Murine RAW 264.7 Macrophages

  2021cites this paper
• Design, synthesis, in vitro determination and molecular docking studies of 4-(1-(tert-butyl)-3-phenyl-1H-pyrazol-4-yl) pyridine derivatives with terminal sulfonamide derivatives in LPS-induced RAW264.7 macrophage cells

  2021cites this paper
• Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis.

  2020cites this paper
• Screening of NO Inhibitor Release Activity from Soft Coral Extracts Origin Palu Bay, Central Sulawesi, Indonesia

  2019cites this paper
• Transition-metal-free regioselective construction of 1,5-diaryl-1,2,3-triazoles through dehydrative cycloaddition of alcohols with aryl azides mediated by SO2F2.

  2019cites this paper
• Inhibitory effects of triarylpyrazole derivatives on LPS-induced nitric oxide and PGE2 productions in murine RAW 264.7 macrophages.

  2019cites this paper
• Copper-catalyzed decarboxylative regioselective synthesis of 1,5-disubstituted 1,2,3-triazoles.

  2018cites this paper
• Synthesis of New Tricyclic and Tetracyclic Fused Coumarin Sulfonate Derivatives and Their Inhibitory Effects on LPS‐Induced Nitric Oxide and PGE2 Productions in RAW 264.7 Macrophages: Part 2

  2016cites this paper
• Las furan-2[5H]-onas (Da,B-butenolidas), su preparación e importancia biológica

  2015cites this paper
• Fluorophore‐Labeled Cyclooxygenase‐2 Inhibitors for the Imaging of Cyclooxygenase‐2 Overexpression in Cancer: Synthesis and Biological Studies

  2014cites this paper
• The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.

  2013cites this paper
• A diazen-1-ium-1,2-diolate analog of 7-azabenzobicyclo[2.2.1]heptane: synthesis, nitric oxide and nitroxyl release, in vitro hemodynamic, and anti-hypertensive studies.

  2013cites this paper
• 1,4-Diaryl-substituted triazoles as cyclooxygenase-2 inhibitors: Synthesis, biological evaluation and molecular modeling studies.

  2013cites this paper
• Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?

  2013cites this paper
• O2-sulfonylethyl protected isopropylamine diazen-1-ium-1,2-diolates as nitroxyl (HNO) donors: synthesis, β-elimination fragmentation, HNO release, positive inotropic properties, and blood pressure lowering studies.

  2012cites this paper
• Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: in-vivo antihyperglycemic activities and blood pressure lowering studies.

  2012cites this paper